Grace Therapeutics, INC Schedule 13G passive stakes

ADAR1 Capital Management, along with affiliates, has reported beneficial ownership of 9.9% of Grace Therapeutics, Inc. common stock, primarily through warrants.

Nantahala Capital Management, LLC, along with its managing members Wilmot B. Harkey and Daniel Mack, has reported beneficial ownership of 6.75% of Grace Therapeutics, Inc. common stock as of June 30, 2026.

ADAR1 Capital Management and Daniel Schneeberger have reported a 9.9% beneficial ownership stake in Grace Therapeutics, Inc. through common stock and warrants.

AIGH Capital Management and affiliated entities report a 4.9% stake in Grace Therapeutics, Inc., primarily through exercisable warrants.

AIGH Capital Management LLC and Orin Hirschman have disclosed a 5.9% beneficial ownership stake in Grace Therapeutics, Inc., holding 907,217 common shares.

ADAR1 Capital Management, ADAR1 Capital Management GP, and Daniel Schneeberger have reported a 9.9% beneficial ownership stake in Grace Therapeutics, Inc. as of September 30, 2025.

Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, reported a 9.99% beneficial ownership stake in Grace Therapeutics, Inc. as of June 30, 2025.

ADAR1 Capital Management, its general partner, and Daniel Schneeberger have filed an amended Schedule 13G, reaffirming a 9.99% beneficial ownership stake in Grace Therapeutics, Inc., primarily through common stock and warrants.

Nantahala Capital Management, along with its managing members Wilmot B. Harkey and Daniel Mack, has disclosed a beneficial ownership of 9.99% in Grace Therapeutics, Inc.'s common stock as of March 31, 2025.

AIGH Capital Management, LLC and Orin Hirschman have filed an amended Schedule 13G, disclosing a 9.9% beneficial ownership stake in Grace Therapeutics, Inc. as of March 31, 2025.

Orin Hirschman and AIGH Capital Management LLC have jointly disclosed a 5.1% beneficial ownership stake in Grace Therapeutics, Inc.'s Common Stock as of December 31, 2024.